ASSIGNMENT AND ASSUMPTION AGREEMENT
EXHIBIT 10.3
ASSIGNMENT AND ASSUMPTION AGREEMENT
This Assignment and Assumption ("Assignment") is effective as of October 03, 2017 ("Effective Date") by and among, Immune Ventures, LLC, a Limited Liability Company formed under the laws of the State of Washington, with principal offices located at 0000 Xxxxx Xxx XX, Xxxxxxx, XX 00000 (“ASSIGNOR”) and INmune Bio Inc., a Nevada corporation, having its principal place of business at 0000 Xxxxxxxx Xx., Xxxxx 000, Xx Xxxxx, XX 00000 (“ASSIGNEE”).
2. ASSIGNOR desires to assign all of its rights, obligations and liabilities under the Exclusive License Agreement to ASSIGNEE;
3. ASSIGNEE desires to accept and assume all of the rights, obligations and liabilities of ASSIGNOR under the Exclusive License Agreement; and
4. In accordance with Article 9 of the Exclusive License Agreement, such assignment and acceptance does not require prior written consent of University.
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as set forth below.
1. ASSIGNOR hereby assigns to ASSIGNEE and ASSIGNEE hereby accepts and assumes all of ASSIGNOR’s rights, obligations and liabilities under the Exclusive License Agreement.
2. The Assignment and any actions arising out of or relating to this Assignment shall be governed by and construed and interpreted in accordance with the laws of the state of California and the United States of America without regard to the conflict of law provisions thereof.
3. ASSIGNOR paid $31,640 (“Costs”) to University of Pittsburgh on August 18, 2017. ASSIGNEE hereby agrees to reimburse said Costs in full by issuing shares at $1.50 per share for 21,094 shares.
IN WITNESS WHEREOF the parties hereto have executed this Assignment as of the Effective Date set forth above.
ASSIGNOR | ASSIGNEE | ||||
|
|
|
|
| |
By: | /s/ Xxxxxxx X. Xxxx | By: | /s/ Xxxxx X. Xxxx | ||
Print Name: | Xxxxxxx X. Xxxx | Print Name: | Xxxxx X. Xxxx | ||
Title: | President and CEO | Title: | Principle | ||
Date: | October 3, 2017 |
| Date: | October 3, 2017 |
|
|